ESMO 2024 | Evaluating the emerging role of radiotherapy and immunotherapy in breast cancer

Alex De Caluwe • 14 Oct 2024

ESMO 2024

Breast Cancer

Alex De Caluwe, MD, Jules Bordet Institute, Brussels, Belgium, comments on how the Neo-CheckRay trial (NCT03875573) is the first trial to test a novel combination of radiotherapy and immunotherapy for breast cancer, focusing on luminal B subtypes. The study aligns with the ongoing P-RAD trial (NCT04443348), which uses a similar approach in both triple-negative and luminal B breast cancer. The combined findings of these trials may reveal new insights into immunotherapy response in traditionally immune-cold breast cancers. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.